ClinicalTrials.gg

Program

orelabrutinib

Also written as “ICP-022”, “Orelabrutinib” and “ICP-248+Orelabrutinib”.

Its studies are mostly in Lymphoma, Mantle-Cell · Lupus Erythematosus, Systemic · Multiple Sclerosis, Chronic Progressive · Purpura, Thrombocytopenic, Idiopathic · Lymphoma, Large B-Cell, Diffuse, led by 2 companies.

Furthest: phase 3, since Oct 1, 202027 company-led studies, 13 open or runningLicense: InnoCare → Zenas BioPharma, Oct 2025Next primary completion: Aug 31, 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
InnoCare Pharma2511 open or runningphase 3since Oct 1, 2020Jun 12, 2017Aug 31, 2028phase 3 · NCT06082102
Zenas BioPharma (USA)22 open or runningphase 3since Jul 3, 2025Jul 3, 2025Jun 2030phase 3 · NCT07299019

How these companies relate

From the companies’ own releases and filings, each linked; the registry does not say.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 13 studies since Jun 12, 2017.

  1. Sep 15, 2021Phase 3 study in Treatment-naїve Mantle Cell LymphomaInnoCare Pharma · NCT05051891 · 3 enrolled · China
  2. Dec 20, 2021Phase 2 study in Purpura, Thrombocytopenic, IdiopathicInnoCare Pharma · NCT05232149 · 30 enrolled · China
  3. Jan 29, 2022Phase 3 study in Lymphoma, Large B-Cell, DiffuseInnoCare Pharma · NCT05234684 · 150 planned · China
  4. Mar 25, 2022Phase 1 study in Healthy PersonInnoCare Pharma · NCT05316857 · 36 enrolled · China
  5. Nov 11, 2022Phase 1 study in Healthy SubjectInnoCare Pharma · NCT05660720 · 48 enrolled · China
  6. Dec 14, 2022Phase 1 study in Hepatic ImpairmentInnoCare Pharma · NCT05684653 · 34 planned · China
  7. Jan 10, 2023Phase 2 study in Lupus Erythematosus, SystemicInnoCare Pharma · NCT05688696 · 186 planned · China
  8. Jan 12, 2023Phase 1 study in Hematologic NeoplasmsInnoCare Pharma · NCT05728658 · 191 planned · China
  9. Jul 11, 2023Phase 2 study in Lymphoma, Mantle-CellInnoCare Pharma · NCT05978739 · 40 enrolled · China
  10. Aug 15, 2023Phase 3 study in Chronic Primary Immune Thrombocytopenia (ITP)InnoCare Pharma · NCT06004856 · 195 planned · China
  11. Oct 8, 2023Phase 3 study in Lymphoma, B-Cell, Marginal ZoneInnoCare Pharma · NCT06082102 · 324 planned · China
  12. Apr 9, 2024Phase 3 study in Lymphoma, Mantle-CellInnoCare Pharma · NCT06363994 · 476 planned · China
  13. Jul 3, 2025Zenas BioPharma (USA)'s first study: phase 3 study in Multiple Sclerosis, Chronic ProgressiveNew to Zenas BioPharma (USA)Zenas BioPharma (USA) · NCT07067463 · 705 planned · United States, Australia, Bulgaria and more
  14. Dec 18, 2025Phase 3 study in Multiple Sclerosis, Chronic ProgressiveZenas BioPharma (USA) · NCT07299019 · 990 planned · United States, Australia, Belgium and more

Ahead

  1. Aug 31, 2028Primary completion: phase 3 study in Lymphoma, B-Cell, Marginal ZoneInnoCare Pharma · NCT06082102
  2. Jun 2030Primary completion: phase 3 study in Multiple Sclerosis, Chronic ProgressiveZenas BioPharma (USA) · NCT07299019
  3. Jun 2030Primary completion: phase 3 study in Multiple Sclerosis, Chronic ProgressiveZenas BioPharma (USA) · NCT07067463
  4. Jun 25, 2031Primary completion: phase 3 study in Lymphoma, Mantle-CellInnoCare Pharma · NCT06363994

TargetBeta

BTK →read by rule
“A small molecule inhibitor of Bruton's tyrosine kinase (BTK; Bruton agammaglobulinemia tyrosine kinase) ”NCIt, by rule
“Tyrosine-protein kinase BTK inhibitor”ChEMBL 37, by rule

Other programs on BTK

ProgramCompanyFurthest phaseStudies
ibrutinibruleJohnson & Johnsonphase 478
acalabrutinibruleAstraZenecaphase 455
zanubrutinibruleBeOne Medicinesphase 435
pirtobrutinibruleEli Lillyphase 430
ritlecitinibrulePfizerphase 342
rilzabrutinibruleSanofiphase 323
evobrutinibruleMerck KGaA, Darmstadt, Germanyphase 320
fenebrutinibHoffmann-La Rochephase 318
nemtabrutinibMerckphase 316
rocbrutinibruleLupeng Pharmaceuticalphase 315
tirabrutinibruleGilead Sciencesphase 313
birelentinibruleDizal Pharmaceuticalsphase 312

Studies

All 27 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07299019Multiple Sclerosis, Chronic Progressive · United States, Australia, Belgium and more3RecruitingZenas BioPharma (USA)Jun 2030990
NCT07067463Multiple Sclerosis, Chronic Progressive · United States, Australia, Bulgaria and more3RecruitingZenas BioPharma (USA)Jun 2030705
NCT06363994Lymphoma, Mantle-Cell · China3RecruitingInnoCare PharmaJun 25, 2031476
NCT06082102Lymphoma, B-Cell, Marginal Zone · China3RecruitingInnoCare PharmaAug 31, 2028324
NCT06004856Chronic Primary Immune Thrombocytopenia (ITP) · China3RecruitingInnoCare PharmaDec 31, 2025195
NCT05978739Lymphoma, Mantle-Cell · China2CompletedInnoCare PharmaDec 10, 202440
NCT05728658Hematologic Neoplasms · China1RecruitingInnoCare PharmaAug 30, 2025191
NCT05688696Lupus Erythematosus, Systemic · China2RecruitingInnoCare PharmaAug 25, 2025186
NCT05684653Hepatic Impairment · China1RecruitingInnoCare PharmaDec 30, 202334
NCT05660720Healthy Subject · China1UNKNOWNInnoCare PharmaJun 30, 202348
NCT05316857Healthy Person · China1CompletedInnoCare PharmaJan 4, 202236
NCT05234684Lymphoma, Large B-Cell, Diffuse · China3RecruitingInnoCare PharmaJul 30, 2024150
NCT05232149Purpura, Thrombocytopenic, Idiopathic · China2UNKNOWNInnoCare PharmaDec 30, 202330
NCT05051891Treatment-naїve Mantle Cell Lymphoma · China3CompletedInnoCare PharmaJun 30, 20253
NCT04711148Multiple Sclerosis, Relapsing-Remitting · United States, China, Poland and more2Active, not recruitingInnoCare PharmaFeb 25, 2026160
NCT04578613Leukemia, Lymphocytic, Chronic, B-Cell · China3RecruitingInnoCare PharmaDec 30, 2024218
NCT04441450Healthy Volunteers · China–CompletedInnoCare PharmaAug 6, 20196
NCT04440059Waldenstrom's Macroglobulinemia Recurrent · China2CompletedInnoCare PharmaJan 9, 202447
NCT04438044Recurrence · China2UNKNOWNInnoCare PharmaDec 31, 202361
NCT04438005Lymphoma, Large B-Cell, Diffuse · China2CompletedInnoCare PharmaNov 5, 20213
NCT04305197Lupus Erythematosus, Systemic · China2CompletedInnoCare PharmaApr 28, 202260
NCT04304040B-cell Lymphoma Recurrent · China2Active, not recruitingInnoCare PharmaDec 30, 202543
NCT04014205Part 1:r/r B-cell Malignancies · United States, Israel, Poland and more2Active, not recruitingInnoCare PharmaJun 30, 202681
NCT03797456MZL · China2CompletedInnoCare PharmaDec 27, 2023111
NCT03494179Lymphoma, Mantle-Cell · China2CompletedInnoCare PharmaApr 10, 2020106
NCT03493217CLL/SLL · China2UNKNOWNInnoCare PharmaDec 31, 2022100
NCT03189017Lupus Erythematosus, Systemic · Australia1CompletedInnoCare PharmaFeb 5, 201864

How it is read

Names in the registry

  • “ICP-022”, 11 entries
  • “Orelabrutinib”, 7 entries
  • “ICP-248+Orelabrutinib”, 3 entries
  • “Orelabrutinib High dose”, 1 entry
  • “Orelabrutinib Low dose”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.